Is it worth buying Natera stock at a price of $45.75? If this question is on your mind, make sure to check out the fundamentals of this Medical Specialities mid-cap company:
-
Natera has logged a 8.0% 52 week change, compared to 23.0% for the S&P 500
-
NTRA has an average analyst rating of buy and is -36.81% away from its mean target price of $72.4 per share
-
Its trailing earnings per share (EPS) is $-4.81, which brings its trailing Price to Earnings (P/E) ratio to -9.5. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $-2.72 and its forward P/E ratio is -16.8
-
The company has a Price to Book (P/B) ratio of 8.75 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 3.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-383804000 and the average free cash flow growth rate is -0.0%
-
Natera's revenues have an average growth rate of 0.0% with operating expenses growing at -36.9%. The company's current operating margins stand at -66.0%